Digital therapeutics company Click Therapeutics has launched a randomised, clinical study with Boehringer Ingelheim aiming to treat the negative symptoms in schizophrenia among adult patients, such as disabling losses of emotion or interest, or withdrawing from social situations. Positive symptoms of schizophrenia include creation of hallucinations and delusions.
The CONVOKE Study, will investigate the use of a prescription digital therapeutic (PDT) as an adjunct treatment to standard of care antipsychotic therapy. The study will enrol approximately 430 adult patients across the U.S., who will undergo a 16-week program combining Click’s PDT with standard of care drug therapies. Efficacy will be assessed by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure scale (CAINS-MAP) to measure experiential negative symptoms.
Schizophrenia is a pervasive, chronic mental disorder affecting 24 million people, or 1 in 300 people worldwide. Currently available medications for schizophrenia mainly treat positive symptoms, with no approved pharmacotherapies or medical devices available to treat the persistent negative symptom, therefore, there is great promise for PDT to alleviate these symptoms.
Click here to read the original news story.